Decitabine-Cedazuridine + Venetoclax for Acute Myeloid Leukemia

This trial tests two medication combinations to find a better treatment for acute myeloid leukemia (AML), a type of blood cancer. The first group will receive decitabine-cedazuridine (a combination drug) and venetoclax, while the second group will receive azacitidine and venetoclax. Individuals with AML that hasn't responded to other treatments or with high-risk blood disorders like myelodysplastic syndrome might be suitable candidates. Participants should have manageable white blood cell counts and be able to take oral medications. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Studies have raised safety concerns about combining azacitidine with venetoclax. This combination increases the risk of serious side effects, such as neutropenia (a low white blood cell count) and anemia (a low red blood cell count), which can lead to infections and fatigue. However, it has successfully extended the lives of some leukemia patients.

Specific safety data for the combination of decitabine-cedazuridine and venetoclax is not available. Since decitabine-cedazuridine is approved for other conditions, it suggests a known level of safety. Venetoclax is also used for other types of leukemia, providing some understanding of its safety.

Researchers are excited about these treatments for acute myeloid leukemia (AML) because they bring new approaches to tackling the disease. The combination of decitabine-cedazuridine with venetoclax in Arm A is unique because decitabine-cedazuridine allows for oral administration, making it more convenient compared to traditional intravenous options. This combination also potentially enhances the cancer-killing effects by combining two mechanisms: decitabine-cedazuridine disrupts DNA methylation, and venetoclax targets and inhibits a protein that cancer cells need to survive. Meanwhile, Arm B combines azacitidine with venetoclax, offering a different approach by using azacitidine to interfere with the growth of cancer cells together with venetoclax. Both approaches aim to improve outcomes for patients with AML by enhancing effectiveness and convenience.

In this trial, participants will receive one of two treatment combinations for acute myeloid leukemia (AML). Research has shown that the combination of decitabine-cedazuridine and venetoclax, which participants in Arm A may receive, effectively treats AML, especially in older adults. One study found that this treatment led to a complete response in 46.5% of patients and either a complete or partial response in 63.4% of patients. Studies also indicate that this treatment can result in long-lasting remissions with manageable side effects.